Understanding ICH Q10: A Non-Certifiable Pharmaceutical Quality System Blueprint

V5 by SG Systems Global is a unified MES–QMS–WMS platform that operationalizes ICH Q10 principles, embedding science- and risk-based quality management into pharmaceutical operations. It facilitates product realization, state of control, and continual improvement through automated workflows for CAPA, change management, performance monitoring, and knowledge capture—ensuring lifecycle compliance without imposing new regulatory burdens.

Adopted in 2008–2009 by regulatory bodies in Europe, Japan, and the United States, ICH Q10 presents a harmonized model for a Pharmaceutical Quality System (PQS) that spans the full lifecycle of a medicinal product—from pharmaceutical development, through technology transfer and commercial manufacturing, to product discontinuation. It integrates ISO quality principles, regional GMP mandates, and science- and risk-based approaches articulated in ICH Q8 and Q9. Importantly, it imposes no new regulatory obligations beyond existing GMP guidance; its additional content is explicitly optional and non-certifiable.

“Implementing ICH Q10 with V5 transformed our PQS—automating risk management and CAPA while enabling real-time continual improvement across the lifecycle.”

— Quality Director, Pharmaceutical Manufacturer

Core Objectives

ICH Q10 defines three interrelated objectives:

• Achieve Product Realisation: Deliver products that meet predefined quality attributes for regulators, healthcare professionals, and patients. This involves establishing, implementing, and maintaining a system to consistently deliver products that comply with approved regulatory filings and satisfy customer needs.
• Establish & Maintain a State of Control: Monitor process performance and product quality effectively, reducing variability and ensuring consistency. This requires developing effective monitoring and control systems to assure continued process capability and product quality.
• Facilitate Continual Improvement: Support innovation, systematic enhancement, and variability reduction based on knowledge and risk-based decisions. This objective focuses on identifying and implementing improvements in product quality, processes, and the PQS itself to enhance reliability and efficiency.

These objectives are designed to be achieved through a lifecycle approach, ensuring that quality is built into the product from the outset and maintained throughout its existence.

Enablers & Operational Subsystems

The guideline specifies two essential enablers:

• Quality Risk Management (per ICH Q9): Structured risk methodology to support decision-making, change evaluation, and control strategy definition. It provides a proactive means to identify, evaluate, and control risks to quality, integrating with continual improvement efforts.
• Knowledge Management: Capture lessons and data from development, tech transfer, manufacturing, and deviations to inform system performance and continual improvement. This involves systematic acquisition, analysis, storage, and dissemination of information from various sources across the product lifecycle.

Core operational subsystems of the PQS include:

• Process Performance & Product Quality Monitoring: A system to monitor and ensure a state of control, using quality risk management to identify improvement areas.
• Corrective & Preventive Action (CAPA): Investigation and action on non-conformances, complaints, and trends to prevent recurrence and enhance understanding.
• Change Management: Systematic evaluation, approval, and review of changes to avoid unintended consequences and support innovation.
• Management Review of PQS performance: Assurance of lifecycle management through reviews of inspections, audits, and performance metrics.

These subsystems work together to maintain the PQS’s effectiveness, with management responsibility ensuring their integration and oversight.

Lifecycle Coverage

ICH Q10 applies to all four lifecycle phases: development, technology transfer, commercial manufacturing, and discontinuation. The system should be implemented in a manner proportionate to the stage and complexity of operations. In pharmaceutical development, it covers designing products and processes; technology transfer involves knowledge sharing between sites; commercial manufacturing focuses on production, control, and improvement; and discontinuation ensures proper documentation retention and product assessment.

This comprehensive coverage ensures that quality management evolves with the product, adapting to each stage’s unique needs and risks.

Empirical Insights & Implementation Challenges

Real-world benchmarking within the St. Gallen OPEX database revealed that implementation of ICH Q10 significantly improved CAPA, performance monitoring, and change management approaches—but management responsibility remained inconsistently embedded in systems, indicating a common implementation gap. The study showed statistically significant improvements in enabler implementation post-ICH Q10, with notable gains in Total Quality Management (mean difference 0.292) and Basic Elements like change management (mean difference 0.181), but a slight decrease in Effective Management System scores, highlighting gaps in management responsibilities.

Common barriers to effective adoption include cultural inertia, siloed knowledge flows, inadequate leadership engagement, and insufficient risk-based governance. Resistance to culture change ranks as the top critical failure factor (12%), with issues like compliance-focused mindsets and regulatory fears stifling innovation. Lack of training (10%) and poor communication from management (9%) further hinder progress, alongside fears of extra validation and submission workloads in a highly regulated environment.

Additional challenges encompass slow adoption due to the guidance’s non-mandatory status, concerns about exposing vulnerabilities, and skill gaps. However, opportunities arise from risk- and science-based approaches, leading to cost savings, efficiency, and better regulatory partnerships.

Digital Enablement & Data Integrity

While ICH Q10 does not mandate specific digital tools, adoption of e-QMS, CAPA management platforms, MES, and electronic batch records substantially strengthens PQS implementation. These systems support automated monitoring, traceability, structured CAPA, and change workflows—but require validation and governance to ensure regulatory compliance and data integrity. Digital platforms like e-QMS centralize processes with version control, electronic signatures, and audit trails to meet ALCOA+ standards, enabling predictive monitoring via AI for anomalies and CAPAs. They enhance traceability across quality events, automate routine tasks, and provide real-time dashboards for compliance readiness, aligning with ICH Q10’s pillars while ensuring data credibility for audits.

Such tools transform reactive systems into proactive ones, reducing variability and facilitating continual improvement without compromising integrity.

Regulatory Position & Strategic Value

Regulators explicitly view ICH Q10 as a guidance model—not a certifiable standard—and reaffirm that compliance is voluntary. Nonetheless, it offers companies a globally aligned framework to build quality systems that support inspections, lifecycle oversight, and cross-border trust. The FDA guidance emphasizes that ICH Q10 creates no new expectations, with additional content optional, and it is not a checklist for inspections or a certifiable standard.

Strategically, adopting ICH Q10 fosters innovation, efficiency, and regulatory confidence, positioning organizations for long-term success in a competitive landscape.

Module Enforcement Map

V5 operationalizes ICH Q10 through synchronized modules:

• MES – Monitors process performance, enforces controls, and captures real-time data for product realization and state of control.
• QMS – Handles CAPA, change management, risk assessments, and knowledge management to drive continual improvement.
• WMS – Ensures traceability, inventory accuracy, and data integrity across the supply chain.
• V5 Unified Platform – Integrates MES, QMS, and WMS for lifecycle-wide PQS support.

Traceability & Lifecycle Readiness

ICH Q10 emphasizes knowledge and risk management across the product lifecycle, where traceability is key for audits and improvements.

V5 enables this with:

• Full audit trails linking development data to manufacturing outcomes.
• Automated knowledge capture from deviations and changes for informed decision-making.
• Real-time dashboards for monitoring lifecycle performance and risks.

This enhances readiness for regulatory reviews and supports proactive quality enhancements.

Why V5 Excels at ICH Q10 Implementation

• Embeds ICH Q10 enablers into digital workflows for seamless risk and knowledge management.
• Aligns with regulatory guidance, supporting voluntary adoption without new obligations.
• Automates subsystems like CAPA and change management to reduce errors and variability.
• Provides immutable records and analytics for continual improvement and state of control.
• Facilitates management reviews with integrated dashboards and reports.
• Ensures data integrity and traceability for audit-ready operations across the lifecycle.

In conclusion, ICH Q10 provides a scientifically grounded, lifecycle-based blueprint for PQS—emphasizing product realization, control, and continual improvement. It is not certifiable in itself. However, organizations implementing integrated digital platforms such as V5 by SG Systems Global can operationalize the guideline’s enablers—CAPA workflows, change control, performance monitoring, traceability, and training logs—in structured, audit-ready ways. While V5 can embody the PQS framework in practice, certification of ICH Q10 remains outside its scope.

Explore pharmaceutical applications and case studies: Pharmaceutical Manufacturing & Compliance.